## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -7.8% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($322.62)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | JP Morgan | $417 | $344 | +21% |
| 2025-11-11 | Wells Fargo | $405 | $354 | +14% |
| 2025-11-10 | TD Cowen | $400 | $350 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | JP Morgan | main | Overweight |
| 2025-11-11 | Wells Fargo | main | Overweight |
| 2025-11-10 | TD Cowen | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.9% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +17%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.82 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Analyst sentiment positive (3 raises, avg +17%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $65.5B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.82 |
| Forward P/E | 17.3 |
| Current P/E | 19.1 |
| YoY Growth | 10.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -4.9% to -7.8% (-2.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.8pp (needs >4.0% for momentum thesis). AM_20 at -5.9% indicates price below own 20MA trend. Underperforming sector by 4.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-5.14), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.83% (CS: 4) | Weak |
| RSI_14 | 39.0 | Neutral |
| MACD Histogram | -5.14 | Bearish |
| vs SMA20 | 0.941x | Below |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 1.130x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $337.82
- **Stop Loss:** $322.62 (4.5% risk)
- **Target:** $353.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 32
- **Position Value:** $10,810.24
- **Portfolio %:** 10.81%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*